The electrocardiograms were compared in two groups of schizophrenic patients (Experimental group N=43, Control group N=60). The selected cases were given 4 mg of Trifluoperazine daily by IM route for five days. A 12 lead ECG was taken thrice in each case. A statistical analysis of the data showed definite changes in many of the ECG variables. Comparatively more changes were noticed in the experimental group and in patients beyond the age of 45 years.
Introduction
The antipsychotic drugs (APD) are known to produce various side-effects. The cardiovascular (CVS) side-effects are more common (Descotes et al. 1979) and are likely to be lethal. These side-effects are more likely to be missed. APD produce myocardial depressant effects which may result in prolonged conduction times, (Yoon et al. 1979 ) delayed refractory periods, diminished cell-membrane ionic permeability (Landmark 1971 (Landmark & 1970 , decreased myocardial contractility (Langer 1968) and repolarization abnormalities (Alvarez-Mena et al. 1973; Thornton and Wendkos 1971; Huston et al. 1966; Wendkos 1964) . These changes usually lead to minor cardiotoxicity and electrocardiographic (ECG) abnormalities though chronic administration of APD may cause cardiomegaly, congestive cardiac failure, refractory arrhythmias (Alexander 1968) and even cardiomyopathy (Inoue 1979 ).
The APD-induced minor cardiotoxicity usually results in "benign" or "nonspecific" ECG changes like prolongation of QT duration (Huston et al. 1966; Watanabe et al. 1973) , T wave changes (Wendkos et al. 1969) ,appearance of Uwave (Ban et al. 1964) , ST depression (Watanabe et al. 1973 ) and slight change in PR interval (Backman et al. 1964) . These changes are seen even in patients without CVS pathology and they usually disappear with discontinuation of APD therapy (Huston et al. 1966) . However, sometimes they may induce serious and potentially fatal arrhythmias e.g. occurrence of ventricular ectopics in a patient with prolonged QT duration may lead to R-on-T phenomenon resulting in ventricular tachycardia and fibrillation. In some instances the myocardial effects may combine with neuroleptic induced hypotension, autonomic and respiratory disturbances to cause sudden death.
The need to study the ECG correlates of longstanding APD therapy is obvious. Curiously enough there are not many ECG studies in patients on long term APD therapy (Fakuda et al. 1982; Schwalbe et al. 1978 The present work was conducted with the aims-1. To study the ECG changes in chronic schizophernic patients and 2. to compare the ECG changes in chronic schizophrenic patients on prolonged antipsychotic medication with patients not on prolonged drug therapy.
Material and Methods
Sample: 103 ambulatory, chronic schizophrenic in-patients of C.I.P., Ranchi were included in the study. They were divided into an experimental group of 43 patients (23 male and 20 female), and a control group of 60 patients (44 male and 16 females). Patients in experimental group were hospitalized continuously for two years or more, whereas control group patients were recently admitted in the hospital.
Selection Criteria:
-Age 18-60 years. -A diagnosis of schizophrenia by Research Diagnostic Criteria (Spitzer et al. 1978 ). -A schizophrenic illness of at least 2 years duration -The patients with evidence of heart disease, either according to history or physical examinations were excluded.
Procedure
After preliminary screening, an informed consent was obtained and possible side-effects of the drug was explained to the patients. A thorough clinical examination including pulse, blood pressure and cardiac status was done in every case. A routine hemogram and a random blood sugar estimation were also done, before the first ECG was taken. The patients in experimental group were kept without antipsychotic drugs for at least 2 weeks to obtain a baseline ECG. No patient on intramuscular fluphenazine decanoate was included in the study for the reason of a long washout period required. The patients included in the control group were only those cases who were on no drugs for 2 weeks or more before their hospitalization.
In selected patients, two milligrams of trifluoperazine via intramuscular route were given twice a day for five days. No other drug was given to the patients during this five days period. A routine, 12 lead ECG in supine position, was taken thrice in each case. The first ECG was a baseline record taken during drug-free period i.e. just before the patient was put on intramuscular trifluoperazine. The second ECG was taken within 24-36 hours of starting the medication, and the last ECG was taken on the 5th day of the drug therapy. In each ECG a long strip was taken in the standard lead II and VI in order to look for any rhythm variation. Each ECG was analysed for its various components, repolarization abnormalities and arrhythmias. Repolarization abnormalities were graded using the criteria of Wendkos (1967) .
Results
Different ECG variables were compared within and between groups using mean, standard deviation, 't' test and percentage values. The results showed that 88.37% of the patients in the experimental group had ECG changes in comparison to 66.67% of the control group. The most common change noticed in the experimental group was the prolonged QTC interval (88.37%). ST depression was found in the experimental group only (23.26%).
Ectopic beats were seen more in the experimental group (4.65%) than the control group (1.67%). Tachycardia and bradycardia were comparatively more common in the control group (Table 1) . A consistently gradual decrease in the mean heart rate was noticed in both the groups in their successive ECG recordings. A statistically significant difference at .05 level has been found between the first and the third tracing and between the second and third tracing of the experimental group, though no such significant difference was noticed between the first and second tracing in the same group. A similar trend of decreasing mean heart rate was found in the control group also but it was not as conspicuous as in the experimental group (Table 2) .
A gradual prolongation of the mean QTC duration (0.41" to 0.456" in males and 0.40" to 0.465" in females) was seen in the successive ECG tracing. The mean QTC duration was found to be increased in the 1st ECG of the experimental groups in comparison to control group. The difference was significant at .01 level. This difference was not significant by the time 3rd ECG record was taken.
Intra-group comparison in male subjects revealed statistically significant difference at .01 level between 1st and 2nd and 3rd ECG record of experimental group. The difference between 2nd and 3rd ECG was not found to be significant. However, in female subjects of the experimental group, this difference among the ECG tracing was not significant.
In both male and female control groups significant difference at .001 level was found between 1st and 2nd and 1st and 3rd ECG records. The difference between 2nd and 3rd ECG record of male group was significant at .02 level whereas in female group this was not found to be significant (Table 3) .
When the ECG changes were correlated with age and duration of illness, a gradual rise in the ECG abnormalities were found with advancing age and chronicity of the illness. A statistically significant difference at .01 level was found between the age range of 31-45 years and 46-60 years. A similar trend (but at .10 level) was noticed between the patients having illness for less than 10 years and those having it for more than 10 years (Table 4) . 
Disscussion
A significant percentage of patients having ECG changes in both the groups clearly shows the CVS side-effects of APD. The ECG changes were found to be comparatively more in patients on prolonged APD therapy. Longterm APD medication has been found to cause more ECG abnormalities (Schwalbe et al. 1978 and Watanahe et al. 1973) .
A gradual diminution in global heart rate was an interesting observation. A similar finding has not been reported in any of the studies though Appleton et al. (1980) mentioned a decrease in the heart rate irr individual cases due to APD.
A very large number of patients showed QTC prolongation. It was seen more in chronic schizophrenic in-patients who were on APD for a long time. Even their basal record (after a washout period of two weeks) showed a prolonged QTC duration. Similar findings were reported by Watanabe et al. (1973) and Schwalbe et al. (1978) . The increase in the QTC duration was much more marked in the first 24-36 hours and it slowed down by the fifth day. Other workers have reported similar finding (Nizamie et al. 1985; Yoon et al. 1979; Langslet 1969; Landmark et al. 1969) . The gradual diminution in prolongation of QTC duration may be a physiological adaptation to the effect of drug (Beckman et al. 1964 ).
Presence of ST segment depression in the experimental group only may be due to prolonged APD therapy. Watanabe et al. (1973) reported ST depression to be the most common finding in a group of schizophrenic patients receiving long-term phenothiazines.
T-wave abnormality in both the groups showed that long term medication as well as exposure to APD for a short period, both can interfere with myocardial repolarization (Schwalbe et al. 1978; Wendkos et al. 1969 ).
Prolongation of myocardial repolarization may also lead to de novo appearance or prominence of existing U-wave (Banetal. 1964; Backmanetal. 1964) . It is believed that phenothiazines shift potassium to the intracellular compartment (Alverez-Mena et al. 1973 ). This results in hypokalemia and consequent upright, prominent U-wave (Goldman 1982) . Oral potassium supplement reverses the repolarization abnormalities secondary to APD (Alverez-Mena et al. 1973) . APD cause both atrial and ventricular ectopics (Langslet 1969; Landmark et al. 1969 ) albeit infrequently (Tatibouet et al. 1980) . In the present study few cases developed ectopic beats. Presence of ectopics in male patients only is an interesting observation. There is some hormonal basis for it, since women have been found to show significantly less cardiac dysrrhythmia than men (Van Diji et al. 1981) .
A very large number of patients (88.89%) beyond the age of 45 years showed ECG changes. It suggested increased susceptibility to cardiotoxicity in older patients. Similarly, patients with longer duration of illness had more of ECG changes. These findings suggest that a patient with longer duration of illness who is in his 40's should be given APD more cautiously.
In conclusion, it may be said that a significant number of patients on APD develop features of cardiotoxicity which becomes more evident in middle aged patients with long duration of illness and on long term APD therapy.
